

Prism Medico & Pharmacy Limited

CIN: L51109PB2002PLC047444

D-118, INDUSTRIAL AREA,
PHASE VII, MOHALI-160055
Telephone no – 0172-5020762

Email Id – investorgrievancewmcl@gmail.com

Date: 14th November, 2018

To,

| | |
|--|--|
| Department of Corporate Services, BSE LIMITED P. J. Towers, Dalal Street, Mumbai – 400 001 | To, Listing Department, Metropolitan Stock Exchange of India Ltd. (MSE) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098, India. |
| ISIN : INE730E01016 | SYMBOL: PRISMEDI |

Subject: Outcome of Board Meeting held on Wednesday, 14th November, 2018.

Scrip ID: 512217

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors in their meeting held on Wednesday, 14th November, 2018 at 4:00 p.m. and concluded at 5.00 p.m.:

1. Consider and Approved and taken on records the Unaudited Financial Results along with Limited Review Report for the Half Year ended on September 30, 2018 as recommended by the Audit Committee.

Further, we hereby enclose the following:


- a. Unaudited Financial Results for the Half Year ended on September 30, 2018.
- b. Limited Review Report from the Statutory Auditor of the Company.

You are requested to take the same on record and acknowledge receipt.

Thanking You,

For, **Prism Medico & Pharmacy Limited**

For PRISM MEDICOS AND PHARMACY LTD.


Gursimran Singh
Director
DIN: 02209675
Authorised Signatory



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report

Review Report To The Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the accompanying statement of Un-Audited Financial Result of **M/s. Prism Medico And Pharmacy Ltd** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter and Half Year ended 30th Sep, 2018 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "*Review of Interim Financial Information performed by the independent auditor of the entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-Audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14-November-2018
Place: Mohali



For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N


CA Suprit Kaur
Partner
M.No 424986

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED/ QUARTER

| PARTICULARS | Quarter Ended (Unaudited) | | | Half Year Ended (Unaudited) | | Year Ended (Audited) |
|--|---------------------------|---------------|---------------|-----------------------------|-----------------|----------------------|
| | 30.09.2018 | 30.06.2018 | 30.09.2017 | 30.09.2018 | 30.09.2017 | 31.03.2018 |
| 1 INCOME FROM OPERATIONS | | | | | | |
| A Net Sales/ Income From Operations | 865.55 | 571.42 | 516.71 | 1436.97 | 1031.50 | 2095.81 |
| B Other Operating Income | 0.00 | 0.00 | | 0.00 | 0.00 | 0.00 |
| TOTAL INCOME FROM OPERATIONS (NET) | 865.55 | 571.42 | 516.71 | 1,436.97 | 1,031.50 | 2,095.81 |
| 2 EXPENSES: | | | | | | |
| Cost of Material Consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Stock-In-Trade | 1316.62 | 456.35 | 496.43 | 1772.97 | 908.01 | 2072.70 |
| Change In Inventories | -501.19 | 85.59 | 0.00 | -415.61 | 79.00 | -9.55 |
| Employee Benefit Expenses | 3.91 | 3.39 | 0.95 | 7.30 | 1.25 | 9.54 |
| Payment to BSE | 1.80 | 3.05 | 0.00 | 4.85 | | 2.88 |
| Depreciation | 0.67 | 0.67 | 0.51 | 1.33 | 1.01 | 4.46 |
| Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately) | 18.24 | 0.87 | 6.13 | 19.11 | 10.27 | 11.10 |
| TOTAL EXPENSES | 840.04 | 549.91 | 504.02 | 1,389.95 | 999.55 | 2,091.13 |
| PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2) | 25.51 | 21.51 | 12.69 | 47.02 | 31.95 | 4.68 |
| 3 Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4) | 25.51 | 21.51 | 12.69 | 47.02 | 31.95 | 4.68 |
| 5 Finance Cost | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 |
| PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6) | 25.50 | 21.50 | 12.69 | 47.01 | 31.95 | 4.66 |
| 7 Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8) | 25.50 | 21.50 | 12.69 | 47.01 | 31.95 | 4.66 |
| 10 TAX EXPENSE: | | | | | | |
| (1) Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.89 |
| (2) Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56 |
| (3) MAT Credit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.89 |
| 11 NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10) | 25.50 | 21.50 | 12.69 | 47.01 | 31.95 | (1.89) |
| 12 Extraordinary Items (Net of Tax ` Expense ____ Lakhs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12) | 25.50 | 21.50 | 12.69 | 47.01 | 31.95 | (1.89) |
| 14 Share of Profit / (loss) of associates * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15 Minority Interest * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 16 NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) * | 25.50 | 21.50 | 12.69 | 47.01 | 31.95 | (1.89) |

PRISM MEDICO AND PHARMACY LTD.

For Signature

| | | | | | | | |
|----|---|--------|--------|--------|--------|--------|--------|
| 7 | Paid-up equity share capital (Face Value of the Share shall be indicated) | 606.34 | 606.34 | 606.34 | 606.34 | 606.34 | 606.34 |
| 18 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | 718.81 | 718.81 | 673.69 | 718.81 | 673.69 | 673.69 |
| 19 | Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised): | | | | | | |
| | (1)BASIC | 0.42 | 0.35 | 0.21 | 0.78 | 0.53 | -0.03 |
| | (2)DILUTED | 0.42 | 0.35 | 0.21 | 0.78 | 0.53 | -0.03 |
| 19 | Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised): | | | | | | |
| | (1)BASIC | 0.42 | 0.35 | 0.21 | 0.78 | 0.53 | -0.03 |
| | (2)DILUTED | 0.42 | 0.35 | 0.21 | 0.78 | 0.53 | -0.03 |


* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH November, 2018.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

Place : Mohali

Date : 14.11.2018

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.
 For PRISM MEDICOS AND PHARMACY LTD.

Gursimran Singh Authorised Signatory
Director
DIN: 02209675

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH SEPTEMBER, 2018

| CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES | | AS ON | AS ON |
|--|--|-----------------|-----------------|
| | | 30.09.2018 | 31.03.2018 |
| I. EQUITY AND LIABILITIES | | | |
| (1) SHAREHOLDER'S FUND | | | |
| (A) SHARE CAPITAL | | 606.34 | 606.34 |
| (B) RESERVES AND SURPLUS | | 718.81 | 671.80 |
| (C) MONEY RECEIVED AGAINST SHARE WARRANTS | | - | - |
| SUB-TOTAL - SHAREHOLDERS' FUNDS | | 1,325.15 | 1,278.14 |
| (2) SHARE APPLICATION MONEY PENDING ALLOTMENT | | | |
| (3) MINORITY INTEREST * | | - | - |
| (4) NON CURRENT LIABILITIES | | | |
| (A) LONG TERM BORROWINGS | | - | - |
| (B) DEFERRED TAX LIABILITIES (NET) | | 6.74 | 6.74 |
| (C) OTHER NON-CURRENT LIABILITIES | | - | - |
| (D) LONG-TERM PROVISIONS | | - | - |
| SUB-TOTAL - NON-CURRENT LIABILITIES | | 6.74 | 6.74 |
| (5) CURRENT LIABILITIES | | | |
| (A) SHORT TERM BORROWINGS | | - | - |
| (B) TRADE PAYABLE | | 502.09 | - |
| (C) OTHER CURRENT LIABILITIES | | 6.30 | 7.89 |
| (D) SHORT TERM PROVISIONS | | - | 0.89 |
| SUB-TOTAL - CURRENT LIABILITIES | | 508.39 | 8.78 |
| TOTAL EQUITY & LIABILITIES | | 1,840.29 | 1,293.67 |
| II. ASSETS | | | |
| (1) NON CURRENT ASSETS | | | |
| (A) FIXED ASSETS | | | |
| (i) TANGIBLE ASSETS | | 9.87 | 11.21 |
| (B) GOODWILL ON CONSOLIDATION * | | - | - |
| (C) NON CURRENT INVESTMENTS | | 1,125.00 | 1,125.00 |
| (D) DEFERRED TAX ASSETS (NET) | | - | - |
| (E) LONG TERM LOANS & ADVANCES | | - | - |
| (F) OTHER NON CURRENT ASSETS | | - | - |
| SUB-TOTAL - NON-CURRENT ASSETS | | 1,134.87 | 1,136.20 |
| (2) CURRENT ASSETS | | | |
| (A) CURRENT INVESTMENTS | | - | - |
| (B) INVENTORIES | | 504.15 | 88.55 |
| (C) TRADE RECEIVABLES | | 121.94 | - |
| (D) CASH AND CASH EQUIVALENTS | | 6.69 | 4.02 |
| (E) SHORT TERM LOANS AND ADVANCES | | 71.75 | 64.01 |
| (F) OTHER CURRENT ASSETS | | 0.89 | 0.89 |
| SUB-TOTAL - CURRENT ASSETS | | 705.42 | 157.46 |
| TOTAL-ASSETS | | 1,840.29 | 1,293.67 |

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.

For PRISM MEDICOS AND PHARMACY LTD.


Gursimran Singh
Director

Authorised Signatory

DIN: 02209675

Place : Mohali

Date : 14.11.2018



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report on Consolidated Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Consolidated Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter and Half Year ended 30th Sep 2018 ("the Statement") and its subsidiary naming M/s Healthy Biosciences Private Limited attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The Consolidated Statement includes the financial results of the following entity naming M/s Healthy Biosciences Private Limited.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Consolidated Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 14-11-2018
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N




CA Suprit Kaur
Partner
M.No 424986

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED/ QUARTER

| PARTICULARS | Quarter Ended (Unaudited) | | | Half Year Ended (Unaudited) | | Year Ended (Audited) |
|---|---------------------------|---------------|----------------|-----------------------------|-----------------|----------------------|
| | 30.09.2018 | 30.06.2018 | 30.09.2017 | 30.09.2018 | 30.09.2017 | 31.03.2018 |
| 1 INCOME FROM OPERATIONS | | | | | | |
| A Net Sales/ Income From Operations | 1500.36 | 576.72 | 561.46 | 2077.08 | 1771.94 | 2280.22 |
| B Other Operating Income | 0.33 | 0.00 | 0.00 | 0.33 | 0.00 | 0.00 |
| TOTAL INCOME FROM OPERATIONS (NET) | 1,500.69 | 576.72 | 561.46 | 2,077.41 | 1,771.94 | 2,280.22 |
| 2 EXPENSES: | | | | | | |
| Cost of Material Consumed | 0.00 | 0.00 | 42.73 | 0.00 | 194.66 | 0.00 |
| Purchase of Stock-In-Trade | 1935.26 | 441.90 | 496.43 | 2377.16 | 1343.80 | 1948.16 |
| Change In Inventories | -491.10 | 85.59 | 0.00 | -405.51 | 106.51 | 179.84 |
| Employee Benefit Expenses | 3.91 | 3.39 | 3.85 | 7.30 | 8.55 | 21.06 |
| Payment to BSE | 1.80 | 3.05 | 0.00 | 4.85 | 0.00 | 2.88 |
| Depreciation | 6.73 | 9.47 | 11.60 | 16.20 | 19.83 | 44.65 |
| Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately) | 18.88 | 1.36 | 14.64 | 20.24 | 31.87 | 52.21 |
| TOTAL EXPENSES | 1,475.49 | 544.75 | 569.25 | 2,020.23 | 1,705.22 | 2,248.80 |
| PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2) | 25.21 | 31.97 | (7.79) | 57.18 | 66.72 | 31.42 |
| 3 Other Income | 5.45 | 0.90 | 0.30 | 6.35 | 1.17 | 4.26 |
| PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4) | 30.66 | 32.87 | (7.49) | 63.53 | 67.89 | 35.68 |
| 5 Finance Cost | 2.91 | 0.94 | 6.48 | 3.86 | 14.22 | 28.87 |
| PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6) | 27.74 | 31.93 | (13.97) | 59.67 | 53.67 | 6.81 |
| 7 Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8) | 27.74 | 31.93 | (13.97) | 59.67 | 53.67 | 6.81 |
| 9 TAX EXPENSE: | | | | | | |
| (1) Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.30 |
| (2) Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.22 |
| (3) MAT Credit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.30 |
| 11 NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10) | 27.74 | 31.93 | (13.97) | 59.67 | 53.67 | (0.41) |
| 12 Extraordinary Items (Net of Tax ` Expense ____ Lakhs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12) | 27.74 | 31.93 | (13.97) | 59.67 | 53.67 | (0.41) |
| 14 Share of Profit / (loss) of associates * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15 Minority Interest * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) * | 27.74 | 31.93 | (13.97) | 59.67 | 53.67 | (0.41) |

For PRISM MEDICOS AND PHARMACY LTD.

| | | | | | | | |
|----|---|--------|--------|--------|--------|--------|--------|
| 17 | Paid-up equity share capital (Face Value of the Share shall be indicated) | 606.34 | 606.34 | 606.34 | 606.34 | 606.34 | 606.34 |
| 18 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | 680.84 | 680.84 | 681.25 | 680.84 | 681.25 | 681.25 |
| 19 | Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised): | | | | | | |
| | (1)BASIC | 0.46 | 0.53 | -0.23 | 0.98 | 0.89 | -0.01 |
| | (2)DILUTED | 0.46 | 0.53 | -0.23 | 0.98 | 0.89 | -0.01 |
| 19 | Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised): | | | | | | |
| | (1)BASIC | 0.46 | 0.53 | -0.23 | 0.98 | 0.89 | -0.01 |
| | (2)DILUTED | 0.46 | 0.53 | -0.23 | 0.98 | 0.89 | -0.01 |

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH November, 2018.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

**FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.**

For PRISM MEDICOS AND PHARMACY LTD.


Gursimran Singh
Authorised Signatory

Director

DIN: 02209675

Place : Mohali

Date : 14.11.2018

PRISM MEDICO AND PHARMACY LTD.


CIN : L51109PB2002PLCO47444

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH. SEPTEMBER, 2018

| CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES | AS ON | AS ON |
|--|-----------------|-----------------|
| | 30.09.2018 | 31.03.2018 |
| I.EQUITY AND LIABILITIES | | |
| (1) SHAREHOLDER'S FUND | | |
| (A) SHARE CAPITAL | 606.34 | 606.34 |
| (B) RESERVES AND SURPLUS | 729.05 | 680.84 |
| (C) MONEY RECEIVED AGAINST SHARE WARRANTS | - | - |
| SUB-TOTAL - SHAREHOLDERS' FUNDS | 1,335.39 | 1,287.19 |
| (2) SHARE APPLICATION MONEY PENDING ALLOTMENT | - | - |
| (3) MINORITY INTEREST * | - | - |
| (4) NON CURRENT LIABILITIES | - | - |
| (A) LONG TERM BORROWINGS | 52.31 | 91.54 |
| (B) DEFERRED TAX LIABILITIES (NET) | 7.49 | 7.49 |
| (C) OTHER NON-CURRENT LIABILITIES | 2.50 | 2.50 |
| (D) LONG-TERM PROVISIONS | - | - |
| SUB-TOTAL - NON-CURRENT LIABILITIES | 62.30 | 101.53 |
| (5) CURRENT LIABILITIES | | |
| (A) SHORT TERM BORROWINGS | 105.71 | 125.16 |
| (B) TRADE PAYABLE | 531.61 | 53.06 |
| (C) OTHER CURRENT LIABILITIES | 6.35 | 11.72 |
| (D) SHORT TERM PROVISIONS | - | 1.30 |
| SUB-TOTAL - CURRENT LIABILITIES | 643.66 | 191.23 |
| TOTAL EQUITY & LIABILITIES | 2,041.35 | 1,579.95 |
| II.ASSETS | | |
| (1) NON CURRENT ASSETS | | |
| (A) FIXED ASSETS | | |
| (i) TANGIBLE ASSETS | 914.45 | 930.65 |
| (B) GOODWILL ON CONSOLIDATION * | - | - |
| (C) NON CURRENT INVESTMENTS | 260.72 | 260.72 |
| (D) DEFERRED TAX ASSETS (NET) | - | - |
| (E) LONG TERM LOANS & ADVANCES | 2.30 | 2.30 |
| (F) OTHER NON CURRENT ASSETS | - | - |
| SUB-TOTAL - NON-CURRENT ASSETS | 1,177.47 | 1,193.66 |
| (2) CURRENT ASSETS | | |
| (A) CURRENT INVESTMENTS | | |
| (B) INVENTORIES | 546.83 | 149.10 |
| (C) TRADE RECEIVABLES | 70.37 | - |
| (D) CASH AND CASH EQUIVALENTS | 67.48 | 135.82 |
| (E) SHORT TERM LOANS AND ADVANCES | 175.54 | 96.01 |
| (F) OTHER CURRENT ASSETS | 3.66 | 5.36 |
| SUB-TOTAL - CURRENT ASSETS | 863.89 | 386.29 |
| TOTAL-ASSETS | 2,041.35 | 1,579.95 |

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

Place : Mohali
Date : 14.11.2018

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.
For PRISM MEDICOS AND PHARMACY LTD.

Gursimran Singh
Director
DIN: 02209675
Authorised Signatory